Diabetes, Metabolic Syndrome and Obesity (May 2020)
Dual Metabolomic Platforms Identified a Novel Urinary Metabolite Signature for Hepatitis B Virus-Infected Patients with Depression
Abstract
Jing Xie,1,* Chang Chen,2,* Li-juan Hou,3 Chan-juan Zhou,4 Liang Fang,5,6 Jian-jun Chen2 1Chongqing Emergency Medical Center, Department of Endocrinology and Nephrology, The Fourth People’s Hospital of Chongqing, Central Hospital of Chongqing University , Chongqing, 400014, People’s Republic of China; 2Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People’s Republic of China; 3Department of Infectious Disease, The First Affiliated Hospital of Xinxiang Medical University, Weihu 453100, Henan, People’s Republic of China; 4NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, Chongqing Medical University, Chongqing 400016, People’s Republic of China; 5Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, People’s Republic of China; 6Chongqing Key Laboratory of Cerebral Vascular Disease Research, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jian-jun ChenInstitute of Life Sciences, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing 400016, People’s Republic of ChinaEmail [email protected] FangDepartment of Neurology, Yongchuan Hospital of Chongqing Medical University, 439 Xuanhua Road, Yongchuan District, Chongqing 402160, People’s Republic of ChinaTel/Fax +86-23-63664754Email [email protected]: Depression could make the treatment outcome worse. However, up to now, no objective methods were developed to diagnose depression in hepatitis B virus (HBV)-infected patients. Therefore, the dual metabolomic platforms were used here to identify potential biomarkers for diagnosing HBV-infected patients with depression (dHB).Methods: Both gas chromatography-mass spectrometry-based and nuclear magnetic resonance-based metabolomic platforms were used to conduct urine metabolic profiling of dHB subjects and HBV-infected patients without depression (HB). Orthogonal partial least-squares discriminant analysis was used to identify the differential metabolites between dHB subjects and HB subjects, and the step-wise logistic regression analysis was used to identify potential biomarkers.Results: In total, 21 important metabolites responsible for distinguishing dHB subjects from HB subjects were identified. Meanwhile, seven potential biomarkers (α-ydroxyisobutyric acid, hippuric acid, azelaic acid, isobutyric acid, malonic acid, levulinic acid, and phenylacetylglycine) were viewed as potential biomarkers. The simplified biomarker panel consisting of these seven metabolites had an excellent diagnostic performance in discriminating dHB subjects from HB subjects. Moreover, this panel could yield a higher accuracy in separating dHB subjects from HB subjects than our previous panels (identified by single metabolomic platform) did.Conclusion: These results suggested that the dual metabolomic platforms could yield a better urinary biomarker panel for dHB subjects than any single metabolomic platform did, and our results could be helpful for developing an objective method in future to diagnose depression in HBV-infected patients.Keywords: hepatitis B virus, depression, metabolomics, biomarker
